Clinical Trial Update: Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update on induction chemotherapy (TPF) for borderline-resectable esophageal squamous cell carcinoma, reporting efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• TPF induction chemotherapy (docetaxel, cisplatin, 5-fluorouracil)

Snippet

Sponsor: Yuhong Li | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED